Back grey_arrow_rt.gif
 
 
GlaxoSmithKline, Pfizer Establish ViiV Healthcare To tackle the increasingly diverse and complex needs of people living with HIV/AIDS worldwide CEO hopes to overtake Gilead, sees Selzentry as key driver
 
 
 
 
Published: 03-Nov-2009
 
Dominique Limet, CEO of the new firm, explained that: "[ViiV's] R&D efforts, strategic partnerships and licensing opportunities will be focussed on delivering medications that help address resistance issues and dosing complexity."
 
Dr Limet stressed that the firm's R&D efforts "will not solely focus on creating 'new' medicines," adding that it will explore the broader potential of all of the molecules in its portfolio. ....."This must continue, but we must also listen and better understand the needs of people living with HIV."
 
"By being 100 per cent dedicated to HIV, we will reach more patients and do much more than either company on its own, with more products, more reach and more focus," Limet says, stressing how the field is evolving as patients with HIV age and develop other illnesses that need to be treated in different ways......"Rising infection rates and increasingly complex treatment issues have created a challenging landscape in the treatment of HIV and the need for innovative research and better patient resources,"
 
"The tie-up, first announced in April, should reinvigorate sales in a "challenging" market sector, said Dominique Limet, the former Glaxo head of personalised medicine who has been appointed chief executive of the new company.......Some drugmakers, including Roche of Switzerland, have stopped researching new HIV drugs in the face of growing pricing pressures and the difficulties of coming up with commercially viable new medicines......."Selzentry will be a key driver and lever for our growth," Limet said......ViiV has a 19 percent share of the global HIV drugs market, while Gilead has 31 percent.....Closing that gap will take a new drive to develop drugs that better address the needs of patients with HIV.......people in developed countries with access to the best care live, on average, 10 years less than those without the virus."
 
Limet also stresses that creating a smaller company focused on a single therapeutic area will rekindle the spirit of innovation by allowing "nimbler responses".

 
Half of ViiV's existing drugs are nucleoside reverse transcriptase inhibitors (NRTIs): Combivir, Epivir/3TC, Epzicom/Kivexa, Retrovir/AZT, Trizivir and Ziagen
 

GSK/Pfizer HIV venture ViiV is launched
 
04 November 2009
 
ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline and Pfizer, has opened its doors for business.
 
The company, which will be 85%-owned by GSK, with Pfizer having a 15% stake, will have 10 products on the market, including GSK's Kivexa (abacavir and lamivudine) and Pfizer's new oral drug Selzentry/Celsentri (maraviroc). Revenues from these generated sales of approximately 1.6 billion in 2008.
 
Dominique Limet, chief executive of ViiV, said that "rising infection rates and increasingly complex treatment issues have created a challenging landscape in the treatment of HIV and the need for innovative research and better patient resources". He added that "much of our historic effort has been led by the virus a chase of science. This must continue, but we must also listen and better understand the needs of people living with HIV".
 
Dr Limet stated that ViiV would be pursuing "multiple" strategies to develop the existing business and deliver "new growth opportunities, including geographic expansion, new collaborations and business development activities". The company also has a pipeline of seven "innovative and targeted medicines", including five compounds in Phase II development and altogether, ViiV has 17 treatments in its portfolio.
 
He added that "one of our first tasks will be to identify partners to help develop fixed-dosed combinations and we are providing 10 million of seed funding to support a public-private partnership approach to the discovery of much-needed clinical evidence into new HIV/AIDS medicines for children". Dr Limet concluded by saying that ViiV had the potential to "re-energise" the pharmaceutical industry's participation in HIV.
 

INTERVIEW-New Glaxo, Pfizer company battles Gilead in HIV
11.03.09, 03:00 AM EST
GLAXO-HIV/ (INTERVIEW):INTERVIEW-New Glaxo, Pfizer company battles Gilead in HIV
 
CEO hopes to overtake Gilead, sees Selzentry as key driver

 
By Ben Hirschler
 
LONDON, Nov 3 (Reuters) - GlaxoSmithKline working alongside Pfizer in an unusual collaboration, aims to regain pole position in the HIV drugs market after being outflanked by Californian upstart Gilead.
 
The two drugmakers are pooling their HIV/AIDS businesses into a new company majority-owned by Glaxo called ViiV Healthcare, which was formally launched on Tuesday.
 
The tie-up, first announced in April, should reinvigorate sales in a "challenging" market sector, said Dominique Limet, the former Glaxo head of personalised medicine who has been appointed chief executive of the new company.
 
Some drugmakers, including Roche of Switzerland, have stopped researching new HIV drugs in the face of growing pricing pressures and the difficulties of coming up with commercially viable new medicines.
 
Glaxo has been struggling. Although its scientists developed the world's first AIDS drug -- AZT -- the British group's products are relatively old and have been losing ground to Gilead's newer and more convenient tablets.
 
Pfizer is a much smaller player in HIV but it has a relatively young portfolio, including the novel drug Selzentry.
 
"Selzentry will be a key driver and lever for our growth," It will allow us to maintain our competitiveness and stabilise, hopefully, over time our market share in front of Gilead," Limet told Reuters.
 
With pro forma sales last year of 1.6 billion pounds ($2.6 billion), ViiV has a 19 percent share of the global HIV drugs market, while Gilead has 31 percent.
 
Closing that gap will take a new drive to develop drugs that better address the needs of patients with HIV -- a condition that has changed from a life-threatening illness into a chronic disease thanks to advances in treatment.
 
NEW DRUG COMBINATIONS
 
Yet while HIV therapy has come a long way, even people in developed countries with access to the best care live, on average, 10 years less than those without the virus.
 
"Our intent is to look at what we can do with the portfolio we get from Pfizer and Glaxo to build new combinations which will completely transform the way we treat HIV," Limet said.
 
By collaborating in this tricky area of medicine Glaxo and Pfizer believe they can trim costs, improve research and increase their combined sales reach.
 
ViiV has 10 marketed medicines and seven in development, including five in mid-stage Phase II clinical trials.
 
Glaxo is the dominant partner in ViiV, reflecting its stronger market position, and has an initial 85 percent stake in the new group, while Pfizer holds 15 percent.
 
The British-based drugmaker's stake could rise to as high as 91 percent or fall to as low as 69.5 percent, depending on the success of drugs from the two contributing businesses in development.
 
For the time being there are no plans to spin off ViiV completely and the group's dedicated staff of around 500 staff will work closely with employees inside Glaxo and Pfizer, who will provide R&D and manufacturing services.
 
In the long term, though, industry analysts believe a flotation could make sense for a company that might be worth $7.5 billion, assuming a valuation of three times sales.
 
"We have to combine two portfolios, set up the right strategy for developing new (drug) combinations, become more attractive -- then it will be up to the shareholders to decide what to do next," Limet said. ($1=.6110 pounds) (Editing by Greg Mahlich)
 

GlaxoSmithKline, Pfizer Establish ViiV Healthcare
Published: 03-Nov-2009
To tackle the increasingly diverse and complex needs of people living with HIV/AIDS worldwide

 
http://www.pharmaceutical-business-review.com
 
GlaxoSmithKline (GSK) and Pfizer have launched ViiV Healthcare, a new specialist HIV company. The newly launched firm aims to tackle the increasingly diverse and complex needs of people living with HIV/AIDS worldwide.
 
Reflecting on the current challenges in HIV and the opportunity for ViiV Healthcare, Dominique Limet, chief executive officer, said: "Rising infection rates and increasingly complex treatment issues have created a challenging landscape in the treatment of HIV and the need for innovative research and better patient resources."
 
"Our ambition is to conduct research and development both inside and outside ViiV Healthcare. Our R&D efforts, strategic partnerships and licensing opportunities will be focused on delivering medications that help address resistance issues and dosing complexity. Within our own pipeline we have some very exciting molecules, including our late stage integrase inhibitor development programme."
 
ViiV Healthcare has signed a research alliance agreement with GSK and Pfizer under which it will invest in research and development into HIV medicines being conducted by both companies. GSK and Pfizer have also agreed to grant ViiV Healthcare a right of first negotiation in relation to any new HIV-related medicine developed by either GSK or Pfizer.
 
ViiV Healthcare has 10 medicines currently available including therapies such as Epzicom/Kivexa (abacavir sulfate+lamivudine) and Selzentry/Celsentri (maraviroc). It also has a pipeline of seven innovative and targeted medicines, including five compounds in phase II development.
 

ViiV Healthcare Lauched in Australia
ViiV Healthcare, a new global specialist HIV company established by
GlaxoSmithKline (GSK) and Pfizer, was officially launched today in Australia.

 
nov 4 2009
 
The creation of ViiV Healthcare demonstrates a strong and sustainable commitment to HIV/AIDS both globally and in Australia. By being solely focused on HIV, ViiV Healthcare will take a deeper and broader interest in the therapy area, particularly areas of high unmet medical need.
 
ViiV Healthcare has a broad treatment portfolio, with ten medicines currently available and a further seven investigational molecules in its pipeline. Revenues from these available treatments will provide ViiV Healthcare with the ability to support sustained investment in its pipeline and community programs.
 
"Globally, Australia is acknowledged for its high quality contributions to HIV research and its excellent support programs for people living with HIV. It is an exciting country in which to be launching ViiV Healthcare, with its sole focus on this important therapy area.
 
"We are looking forward to bringing the benefits of the combination of a broad product portfolio, commitment to research into new treatments and a strong community focus to people living with HIV in Australia," said Robert Knesaurek, Country Manager of ViiV Healthcare in Australia.
 
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org